Avonex, Interferon Beta-1a Wire
Comprehensive News Feed for Avonex, Interferon Beta-1a (generic).
Results 1 - 20 of 34 in Avonex, Interferon Beta-1a (generic)
-
FDA Holds Up Merck KGaA's Multiple Sclerosis Pill
EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, announced today that it received a refuse to file letter from the US Food and Drug Administration on the New Drug Application for Cladribine Tablets, EMD Serono's proprietary investigational oral formulation of cladribine, as a therapy for relapsing forms of multiple sclerosis . Comment?
-
Merck Serono Receives Refuse to File Letter From FDA on Cladribine Tablets New Drug Application
"The company will work closely with the FDA to fully understand FDA's concerns and define a path forward for a successful resubmission of this application at the earliest point in time," said , President of Merck Serono. Comment?
-
Merck Serono Receives Refuse to File Letter From FDA on Cladribine Tablets New Drug Application
"The company will work closely with the FDA to fully understand FDA's concerns and define a path forward for a successful resubmission of this application at the earliest point in time," said Elmar Schnee , President of Merck Serono. Comment?
-
Childbirth May Slow Progression of Multiple Sclerosis
w/Photo
Having children may slow the progression of multiple sclerosis, new research suggests. Comment?
-
Whatever Tysabri Outcome, Biogen Idec Should Survive
Biogen Idec 's key multiple sclerosis drug is in the news again, as the European Medicines Agency has started a safety review of Tysabri , citing more confirmed cases of a rare - but potentially fatal - viral infection of the brain, called progressive multifocal leukoencephalopathy , previously linked to the drug. Comment?
-
EMD Serono, Inc. Named as a Top Employer by Science Magazine
EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced today that Science magazine has named it one of the world's leading biotechnology and pharmaceutical employers. Comment?
-
Compelling new data on Novartis' oral MS therapy
Two-year Phase III study shows Novartis oral MS therapy FTY720 significantly reduces relapses and disability progression * FREEDOMS study shows FTY720 reduced relapse rates by 54-60% compared to placebo, and disability progression by 30-32%[1] * Results build on Phase III TRANSFORMS one-year study showing FTY720 reduced relapses significantly more ... Comment?
-
Oral Pill Fingolimod Reduces Relapses And Disability Progression
Drug manufacturer Novartis has announced further results from its phase III study of the oral pill fingolimod in people with relapsing remitting multiple sclerosis . Comment?
-
Clinical trial results conclude Novartis' MS drug yields 'significant' results
BASEL,A Switzerland Patients taking an investigational drug for multiple sclerosis experienced a oesignificanta reductions in relapses and disability progression, according to results of a late-stage clinical trial released Wednesday. Comment?
-
Two-year Phase III study shows Novartis oral MS therapy FTY720...
The issuer is solely responsible for the content of this announcement. -------------- * FREEDOMS study shows FTY720 reduced relapse rates by 54-60% compared to placebo, and disability progression by 30-32%[1] * Results build on Phase III TRANSFORMS one-year study showing FTY720 ... Comment?
-
Results From Improve Study Show MRI Benefits of Rebif(R) Seen Early...
Data Presented at the 25th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis Held in Dusseldorf, Germany, From September 9-12, 2009. Comment?
-
AVONEX results in few injection site reactions, according to a clinical study
Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis patients taking AVONEX reported significantly fewer injection site reactions compared to patients on Betaferon- , Copaxone- or Rebif - . The study also showed AVONEX patients were less likely to have missed a dose due to an ... Comment?
-
Phase 2 MS clinical trial data continues to show durable reductions in relapse rate
Genzyme Corporation reported today that four-year follow-up data from its completed Phase 2 multiple sclerosis trial continued to show durable reductions in relapse rate and sustained accumulation of disability three years after the majority of patients received their last course of the investigational compound alemtuzumab. Comment?
-
Fewer Injection Site Reactions In Patients Using AVONEX Versus...
Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis patients taking AVONEX reported significantly fewer injection site reactions compared to patients on Betaferon , Copaxone or Rebif . Comment?
-
Patients using Avonex have few site reactions
Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis patients taking AVONEX reported significantly fewer injection site reactions compared to patients on BetaferonA , CopaxoneA or Rebif A . The study also showed AVONEX patients were less likely to have missed a dose due to an ... Comment?
-
Genzyme announces results from Phase II of alemtuzumab in multiple sclerosis
The CAMMS223 Phase II trial compared alemtuzumab to an approved MS therapy Rebif in early, relapsing-remitting multiple sclerosis patients who had received no prior therapy. Comment?
-
Genzyme's Alemtuzumab for Multiple Sclerosis Shows Durable Treatment...
Sep 11, 2009 - Genzyme Corporation reported today that four-year follow-up data from its completed Phase 2 multiple sclerosis trial continued to show durable reductions in relapse rate and sustained accumulation of disability three years after the majority of patients received their last course of the investigational compound alemtuzumab. Comment?
-
Fewer Injection Site Reactions in Patients Using Avonex Versus...
Sep 11, 2009 - Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis patients taking AVONEX reported significantly fewer injection site reactions compared to patients on Betaferon , Copaxone or Rebif . Comment?
-
Results from IMPROVE Study Show MRI Benefits of Rebif Seen Early in...
Results from IMPROVE Study Show MRI Benefits of Rebif Seen Early in Relapsing-Remitting Multiple Sclerosis Treatment and Sustained Over Time Data presented at the 25th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis held in Duesseldorf, Germany, from September 9-12, 2009. Comment?
-
16:41]( ... )- ' ' s Y - Y - BW- Fewer Injection Site...
I'I I'IsIYI I I I I- I I I IYI - BW- Fewer Injection Site Reactions in Patients Using AVONEXA Versus Sub... Fewer Injection Site Reactions in Patients Using AVONEXA Versus Sub-cutaneous Interferon and Glatiramer Acetate for the Treatment of Multiple Sclerosis CAMBRIDGE, Mass.-- -- Data from an observational phase IV study of 499 patients ... Comment?
Avonex, Interferon Beta-1a Forum
Most Popular
- Tiger Woods alienates black community with white lovers? Garbage - 367 comments
- Man arrested for throwing a tomato at Sarah Palin during Mall of America 'Goi... - 398 comments
- 100 year old, unrepentant pedophile to be released from jail - 219 comments
- Sexual rights group renames female hymen - 147 comments
- Obama defends US wars as he accepts peace prize - 136 comments
- Doctor fatally shot at medical clinic in Hazard Kentucky. - 206 comments
- Brooklyn Teachers Caught Naked in Empty Classroom - 104 comments
- House passes $447 billion spending bill - 92 comments
- Vandals Target Nativity Displays in NJ - 131 comments
- Nobel award in hand, Obama faces hard work at home - 68 comments
|
Reach local customers. Engage a specific demographic. Maximize business-to-business opportunities. Topix can deliver your message.
|
Copyright ©2009 Topix LLC
